If you have questions, please call us for more information about clinical trials or use our online form.
- Cancer clinical trials: 414-805-8900
- Noncancer clinical trials: 414-955-8555
Learn more about clinical trials basics and early-phase clinical trials, as well as some of the unique features our research program, including our Translational Research Unit. Froedtert & MCW health network is also part of the National Institutes of Health All of Us Research Program.
Displaying 1 - 10 of 10
A Multi-Center Single Arm Phase II Study to Evaluate the Safety and Efficacy of Genetically Engineered Autologous Cells Expressing Anti-CD20 and Anti-CD19 Specific Chimeric Antigen Receptor in Subjects with Relapsed and/or Refractory Diffuse Large B
Objective
Phase II MB-CART2019.1 for R/R DLBCL
Protocol No
MILTENYI-MB-CART2019-1-DLBCL
Categories
A Phase III Randomized Trial of Steroids + Tyrosine Kinase Inhibitor (TKI) Induction with Chemotherapy or Blinatumomab for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia (ALL) in Adults
Objective
Steroids plus TKI with Blinatumomab or Chemo for Newly Diagnosed BCR-ABL Positive ALL in Adults
Protocol No
ECOG-EA9181-ALL
Categories
A Phase 1, Multicenter, Open-Label Study of CB-010, a CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy in Patients with Relapsed/Refractory B Cell Non-Hodgkin Lymphoma
Objective
CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell NHL
Protocol No
CARIBOU-CB10A-ANTLER-NHL
Categories
Phase I/II Study of Tandem, Bispecific Anti-CD19 Anti-CD20 CAR-T Cells for Patients with Relapsed and/or Refractory B Cell Malignancies
Objective
Study of tandem, bispecific anti-CD19 anti-CD20 CAR-T cells for Patients with Relapsed and/or Refractory B Cell Malignancies
Protocol No
IIT-SHAH-IL7-IL15-CD20-19
Categories
Phase I Study of LV20.19 CAR T-Cells in Combination with Pirtobrutinib for Relapsed, Refractory B-Cell Malignancies
Objective
Phase I Study of LV20.19 CAR T-Cells in Combination with Pirtobrutinib for Relapsed, Refractory B-cell Malignancies
Protocol No
IIT-SHAH-PIRTO
Categories
A Phase 1b/2 Study of GC012F, a Chimeric Antigen Receptor T-Cell (CAR-T) Therapy Targeting CD19 and B-cell Maturation Antigen (BCMA) in Subjects with Relapsed/Refractory Multiple Myeloma
Objective
Study of GC012F, CAR-T Therapy Targeting CD19 and BCMA in subjects with r/r MM
Protocol No
GRACELL-GC012F-CD19-BCMA-001
An Open-Label, Phase 1/2 Study of JCAR017 in Subjects with Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (017004)
Objective
Study Evaluating Safety and Efficacy of JCAR017 in Subject with rrCLL or SLL
Protocol No
JUNO-017004-TRANSCEND-CLL
Categories
A Randomized Phase II Study of Venetoclax and HMA-Based Therapies for the Treatment of Older and Unfit Adults with Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia (AML): A MyeloMATCH Treatment Trial
Objective
Venetoclax and HMA Treatment of Older and Unfit Adults with FLT3 Mutated Acute Myeloid Leukemia (AML)
Protocol No
ECOG-MM1OA-EA02
Categories
A Phase 1b/2, Open-Label, Dose Finding and Expansion Study of BGB-16673 in Combination with Other Agents in Relapsed or Refractory B-Cell Malignancies
Objective
Study of BGB-16673 in combination with other agents for patients with R/R B-cell malignancies
Protocol No
BEIGENE-BGB-16673-104
Categories
An Open-Label Phase 1b Study Evaluating the Safety and Efficacy of Etentamig (ABBV-383) in AL Amyloidosis
Objective
Study of ABBV-383 for AL amyloidosis
Protocol No
ABBVIE-M24-209
Categories